<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain Circ</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Circ</journal-id>
<journal-id journal-id-type="publisher-id">BC</journal-id>
<journal-title-group>
<journal-title>Brain Circulation</journal-title>
</journal-title-group>
<issn pub-type="ppub">2394-8108</issn>
<issn pub-type="epub">2455-4626</issn>
<publisher>
<publisher-name>Wolters Kluwer - Medknow</publisher-name>
<publisher-loc>India</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31334360</article-id>
<article-id pub-id-type="pmc">6611193</article-id>
<article-id pub-id-type="publisher-id">BC-5-74</article-id>
<article-id pub-id-type="doi">10.4103/bc.bc_7_19</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The neuroprotective mechanisms and effects of sulforaphane</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Klomparens</surname>
<given-names>Eric A</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ding</surname>
<given-names>Yuchuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<italic>Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA</italic>
</aff>
<aff id="aff2">
<label>2</label>
<italic>John D. Dingell VA Medical Center, Detroit, MI, USA</italic>
</aff>
<author-notes>
<corresp id="cor1"><bold>Address for correspondence:</bold> Prof. Yuchuan Ding, Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA. E-mail: <email xlink:href="yding@med.wayne.edu">yding@med.wayne.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<season>Apr-Jun</season>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>6</month>
<year>2019</year>
</pub-date>
<volume>5</volume>
<issue>2</issue>
<fpage>74</fpage>
<lpage>83</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>12</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2019 Brain Circulation</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0">
<license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p>
</license>
</permissions>
<abstract>
<p>Sulforaphane (SFN) is a phytochemical found in cruciferous vegetables. It has been shown to have many protective effects against many diseases, including multiple types of cancer. SFN is a potent activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant response element (ARE) genetic pathway. Upregulation of Nrf2-ARE increases the availability of multiple antioxidants. A substantial amount of preclinical research regarding the ability of SFN to protect the nervous system from many diseases and toxins has been done, but only a few small human trials have been completed. Preclinical data suggest that SFN protects the nervous system through multiple mechanisms and may help reduce the risk of many diseases and reduce the burden of symptoms in existing conditions. This review focuses on the literature regarding the protective effects of SFN on the nervous system. A discussion of neuroprotective mechanisms is followed by a discussion of the protective effects elicited by SFN administration in a multitude of neurological diseases and toxin exposures. SFN is a promising neuroprotective phytochemical which needs further human trials to evaluate its efficacy in preventing and decreasing the burden of many neurological diseases.</p>
</abstract>
<kwd-group>
<kwd>Antioxidant</kwd>
<kwd>autism spectrum disorder</kwd>
<kwd>broccoli sprouts</kwd>
<kwd>epilepsy</kwd>
<kwd>isothiocyanate</kwd>
<kwd>neurodegenerative disease</kwd>
<kwd>nuclear factor erythroid 2-related factor 2</kwd>
<kwd>phytochemical</kwd>
<kwd>schizophrenia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1" sec-type="intro">
<title>Introduction</title>
<p>Sulforaphane (SFN) is a phytochemical whose precursor glucoraphanin is found in cruciferous vegetables, with the highest concentrations in broccoli sprouts.[<xref ref-type="bibr" rid="ref1">1</xref>] SFN belongs to the group of plant-derived compounds called isothiocyanates. It is known for a being a powerful inducer of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway which plays a major role in upregulating cellular defenses to oxidative stress.[<xref ref-type="bibr" rid="ref2">2</xref>] SFN has been studied intensely regarding its ability to decrease the risk of various cancers and reduce the damage associated with varying forms of oxidative stress.[<xref ref-type="bibr" rid="ref3">3</xref>]</p>
<p>More recently, a variety of preclinical research regarding the role of SFN in neuroprotection has been conducted with very promising results. Only a few human trials regarding the protective effects of SFN in the nervous system have been done; however, SFN has very strong antioxidant and anti-inflammatory properties which allow it to dramatically reduce cytotoxicity in the nervous system, with apparently very little toxicity of its own within the therapeutic range.[<xref ref-type="bibr" rid="ref4">4</xref>] Animal studies suggest that SFN supplementation could be disease-modifying for many common, debilitating central nervous system (CNS) diseases including Alzheimer's disease, Parkinson's disease, epilepsy, stroke, and others.</p>
<p>To fully assess the research that has been completed regarding the neuroprotective effects of SFN, a literature search was done using MEDLINE for relevant articles published as of January 2019. The literature search included the following keywords: SFN, neuroprotection, neurodegeneration, nervous system, neuron, brain, neurogenesis, and Nrf2. Resulting articles were reviewed for relevance to the topic of neuroprotection. The dates of included publications range from 2004 to 2018. This review focuses on the research that has been completed regarding the neuroprotective properties of SFN in various disease states and toxin exposures. The mechanisms underlying SFN's protective properties will be discussed first, followed by the effects seen in various disease models.</p>
</sec>
<sec id="sec1-2">
<title>Mechanisms of Neuroprotection</title>
<p>SFN is a well-known powerful inducer of the Nrf2-ARE pathway, which has been coined the “guardian of redox homeostasis.”[<xref ref-type="bibr" rid="ref5">5</xref><xref ref-type="bibr" rid="ref6">6</xref>] The activation of the Nrf2-ARE pathway leads to upregulation of many downstream products involved in protection against oxidative stress, including NAD(P)H quinone oxidoreductase 1, heme oxygenase 1, glutathione (GSH) peroxidase 1,[<xref ref-type="bibr" rid="ref7">7</xref>] and gamma-glutamylcysteine synthetase, an important rate-limiting enzyme which controls the rate of GSH synthesis.[<xref ref-type="bibr" rid="ref8">8</xref>] The adequate availability of reduced GSH is vital to avoid the damage induced by free radicals.[<xref ref-type="bibr" rid="ref8">8</xref>] SFN increases GSH release by up to 2.4-fold in cultured astrocytes[<xref ref-type="bibr" rid="ref8">8</xref>] and has been shown to reduce oxidative stress in multiple disease states in cultured cells and animal models.[<xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref10">10</xref><xref ref-type="bibr" rid="ref11">11</xref><xref ref-type="bibr" rid="ref12">12</xref><xref ref-type="bibr" rid="ref13">13</xref><xref ref-type="bibr" rid="ref14">14</xref>] A brief study in humans revealed that SFN increases the amount of GSH in the brain after 7 days of administration, which provides evidence that the antioxidant pathways activated by SFN are present in humans.[<xref ref-type="bibr" rid="ref15">15</xref>] The Nrf2 pathway is vital for many of SFN's protective effects, as evidenced by a lack of neuroprotection from multiple toxins when SFN is given with an inhibitor of gamma-glutamylcysteine synthetase[<xref ref-type="bibr" rid="ref16">16</xref>] or in Nrf2-knockout mice.[<xref ref-type="bibr" rid="ref17">17</xref><xref ref-type="bibr" rid="ref18">18</xref>] Nrf2-ARE plays a vital role in the protective effect of SFN against many diseases, including Parkinson's disease, neuropathy, Friedrich's ataxia, stroke, and Alzheimer's disease.[<xref ref-type="bibr" rid="ref19">19</xref><xref ref-type="bibr" rid="ref20">20</xref><xref ref-type="bibr" rid="ref21">21</xref><xref ref-type="bibr" rid="ref22">22</xref><xref ref-type="bibr" rid="ref23">23</xref>]</p>
<p>Besides its promotion of antioxidant defenses, SFN also significantly lessens inflammatory responses to pathologic states, thus reducing the amount of damage done due to the body's immune response.[<xref ref-type="bibr" rid="ref24">24</xref>] SFN reduces damage to neurons mediated by microglia by promoting polarization of microglia from the M1 to the anti-inflammatory M2 type,[<xref ref-type="bibr" rid="ref25">25</xref><xref ref-type="bibr" rid="ref26">26</xref>] thus down regulating the mRNA and proteins levels of multiple inflammatory mediators, including tumor necrosis factor-α, interleukin (IL)-1 β, IL-6, cyclooxygenase 2, and inducible nitric oxide synthetase.[<xref ref-type="bibr" rid="ref5">5</xref><xref ref-type="bibr" rid="ref11">11</xref><xref ref-type="bibr" rid="ref24">24</xref><xref ref-type="bibr" rid="ref27">27</xref><xref ref-type="bibr" rid="ref28">28</xref>] Furthermore, SFN decreases the activation of multiple mitogen-activated protein kinases and other inflammatory mediators, including nuclear factor κB, RIPK3, and MLKL, resulting in reduced neuronal apoptosis and necrosis.[<xref ref-type="bibr" rid="ref24">24</xref>] Interestingly, when the immune system is needed such as when cancer is present, however, SFN inhibits the ability of glioblastoma multiforme to create a supportive immunosuppressed environment by disallowing the transformation of monocytes into myeloid-derived suppressor cells.[<xref ref-type="bibr" rid="ref29">29</xref>] SFN also reduces cleavage of caspase-1 and caspase-3,[<xref ref-type="bibr" rid="ref12">12</xref><xref ref-type="bibr" rid="ref30">30</xref><xref ref-type="bibr" rid="ref31">31</xref><xref ref-type="bibr" rid="ref32">32</xref><xref ref-type="bibr" rid="ref33">33</xref>] increases the production of the anti-inflammatory cytokines IL-4 and IL-10,[<xref ref-type="bibr" rid="ref25">25</xref><xref ref-type="bibr" rid="ref34">34</xref>] and reduces the amount of gliosis, apoptosis, and necrosis in response to toxins.[<xref ref-type="bibr" rid="ref11">11</xref><xref ref-type="bibr" rid="ref17">17</xref><xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref27">27</xref><xref ref-type="bibr" rid="ref31">31</xref><xref ref-type="bibr" rid="ref35">35</xref><xref ref-type="bibr" rid="ref36">36</xref>] The reduction of neuroinflammation plays a prominent role in protecting against many toxins, as well as neuronal damage associated with Alzheimer's disease, Parkinson's disease, epileptic seizures, cerebral infarction, hepatic encephalopathy, Huntington's disease, and spinal cord injury.[<xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref10">10</xref><xref ref-type="bibr" rid="ref11">11</xref><xref ref-type="bibr" rid="ref17">17</xref><xref ref-type="bibr" rid="ref25">25</xref><xref ref-type="bibr" rid="ref26">26</xref><xref ref-type="bibr" rid="ref30">30</xref><xref ref-type="bibr" rid="ref37">37</xref><xref ref-type="bibr" rid="ref38">38</xref>] Oxidative stress and inflammation are major causes of cellular damage in a vast array of neurological diseases, and so by reducing both of these factors, SFN has major promise for helping protect against this damage.</p>
<p>Autophagy, a process used by cells to degrade damaged organelles and harmful proteins,[<xref ref-type="bibr" rid="ref19">19</xref>] is also upregulated by SFN in neurons.[<xref ref-type="bibr" rid="ref19">19</xref><xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref39">39</xref><xref ref-type="bibr" rid="ref40">40</xref>] One study found that the promotion of autophagy by SFN is partially dependent on the Nrf2-ARE pathway, as indicated by Nrf2-knockout mice expressing fewer autophagy genes as well as the rescue of this expression by infection with an Nrf2-expressing lentivirus.[<xref ref-type="bibr" rid="ref19">19</xref>] However, a separate study found that Nrf2 knockdown did not influence autophagy.[<xref ref-type="bibr" rid="ref40">40</xref>] SFN produces oxidative stress itself, which is necessary for the upregulation of autophagy, evidenced by a lack of this upregulation when neurons are co-treated with SFN and the potent antioxidant N-acetyl-l-cysteine.[<xref ref-type="bibr" rid="ref40">40</xref>] The upregulation of autophagy by SFN plays a role in its neuroprotection in many neurodegenerative diseases by increasing the breakdown of the harmful proteins that characterize these diseases, including Alzheimer's disease,[<xref ref-type="bibr" rid="ref19">19</xref>] Parkinson's disease,[<xref ref-type="bibr" rid="ref23">23</xref>] and prion diseases.[<xref ref-type="bibr" rid="ref39">39</xref>]</p>
<p>SFN also protects mitochondrial function in neurons.[<xref ref-type="bibr" rid="ref22">22</xref><xref ref-type="bibr" rid="ref41">41</xref><xref ref-type="bibr" rid="ref42">42</xref><xref ref-type="bibr" rid="ref43">43</xref><xref ref-type="bibr" rid="ref44">44</xref>] Neurons, which are highly metabolically active and rely on oxidative phosphorylation to keep up with energy demands, depend on healthy mitochondria.[<xref ref-type="bibr" rid="ref43">43</xref>] The Nrf2-ARE pathway activates multiple genes which promote mitochondrial biogenesis, protect the function of mitochondrial complex I, II, and IV, and inhibit the decrease in adenosine triphosphate (ATP) generation caused by toxins.[<xref ref-type="bibr" rid="ref42">42</xref>] The upregulation of antioxidant defenses by the Nrf2-ARE pathway also works to protect the mitochondria from damage.[<xref ref-type="bibr" rid="ref43">43</xref>] Mitochondrial protection plays a role in reducing damage due to epileptic seizures,[<xref ref-type="bibr" rid="ref44">44</xref>] chemotherapy-induced neuropathy,[<xref ref-type="bibr" rid="ref5">5</xref>] models of Huntington's disease,[<xref ref-type="bibr" rid="ref42">42</xref>] neurodegenerative diseases,[<xref ref-type="bibr" rid="ref43">43</xref>] and carbon monoxide exposure.[<xref ref-type="bibr" rid="ref41">41</xref>]</p>
<p>Neurogenesis, the production of new neurons from neural stem cells, is critically important for learning and memory, and it is dysregulated in many neurodegenerative diseases.[<xref ref-type="bibr" rid="ref3">3</xref>] SFN increases neuronal expression of brain-derived neurotrophic factor, which promotes neuron generation[<xref ref-type="bibr" rid="ref3">3</xref>] and upregulates Wnt signaling in neural stem cells, which then increases stem cell proliferation and their differentiation into neurons.[<xref ref-type="bibr" rid="ref45">45</xref>]</p>
</sec>
<sec id="sec1-3">
<title>Neuroprotection in Disease and Toxin Exposure</title>
<p><xref ref-type="table" rid="T1">Table 1</xref> provides a tabular view of the major evidence for the neuroprotective effects of SFN, categorized by disease.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Summary of major findings related to the neuroprotective effects of sulforaphane in various neurologic disease states</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Topic</th>
<th align="left" colspan="1" rowspan="1">Article</th>
<th align="left" colspan="1" rowspan="1">Model</th>
<th align="left" colspan="1" rowspan="1">Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="4" rowspan="1">Neurodegeneration</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">AD</td>
<td align="left" colspan="1" rowspan="1">Hou <italic>et al</italic>., 2018; Lee <italic>et al</italic>., 2018</td>
<td align="left" colspan="1" rowspan="1">Mouse transgenic AD</td>
<td align="left" colspan="1" rowspan="1">Reduced amount of Aβ and phosphorylated tau and their aggregation in the brain; reduced memory deficits</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zhang <italic>et al</italic>., 2014</td>
<td align="left" colspan="1" rowspan="1">Mouse aluminum and D-galactose-induced AD</td>
<td align="left" colspan="1" rowspan="1">Reduced cholinergic neuron loss in hippocampus and septum</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Angeloni <italic>et al</italic>., 2015</td>
<td align="left" colspan="1" rowspan="1">Cultured neurons with methylglyoxal</td>
<td align="left" colspan="1" rowspan="1">Reduced cell death</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Park <italic>et al</italic>., 2009</td>
<td align="left" colspan="1" rowspan="1">Cultured neurons with Aβ</td>
<td align="left" colspan="1" rowspan="1">Reduced cell death</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">Memory</td>
<td align="left" colspan="1" rowspan="1">Wang <italic>et al</italic>., 2016</td>
<td align="left" colspan="1" rowspan="1">Rat streptozotocin-induced DM</td>
<td align="left" colspan="1" rowspan="1">Reduced apoptosis of hippocampal neurons; reduced memory impairment</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Sunkaria <italic>et al</italic>., 2018</td>
<td align="left" colspan="1" rowspan="1">Mouse MG132 exposure</td>
<td align="left" colspan="1" rowspan="1">Protection against loss of spatial memory and memory consolidation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lee S <italic>et al</italic>., 2014</td>
<td align="left" colspan="1" rowspan="1">Mouse scopolamine exposure</td>
<td align="left" colspan="1" rowspan="1">Protection against memory loss; increased level of ACh in hippocampus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6">PD</td>
<td align="left" colspan="1" rowspan="1">Zhou <italic>et al</italic>., 2016</td>
<td align="left" colspan="1" rowspan="1">Mouse rotenone-induced PD</td>
<td align="left" colspan="1" rowspan="1">Improved locomotor activity; reduced dopaminergic neuron loss in brain</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Morroni <italic>et al</italic>., 2013</td>
<td align="left" colspan="1" rowspan="1">Mouse 6-hydroxydopamine-induced PD</td>
<td align="left" colspan="1" rowspan="1">Improved motor coordination; reduced neuron apoptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Morroni <italic>et al</italic>., 2018; Deng <italic>et al</italic>., 2012</td>
<td align="left" colspan="1" rowspan="1">Mouse 6-hydroxydopamine-induced PD</td>
<td align="left" colspan="1" rowspan="1">Reduced dopaminergic neuron loss</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Vauzour <italic>et al</italic>., 2010</td>
<td align="left" colspan="1" rowspan="1">Cultured cortical neurons with 5-S-cysteinyl-dopamine</td>
<td align="left" colspan="1" rowspan="1">Reduced neuron loss</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Jazwa <italic>et al</italic>., 2011</td>
<td align="left" colspan="1" rowspan="1">Mouse MPTP-induced PD</td>
<td align="left" colspan="1" rowspan="1">Reduced loss of nigral dopaminergic neurons</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Siebert <italic>et al</italic>., 2009</td>
<td align="left" colspan="1" rowspan="1">Nigrostriatal culture of rat brain exposed to 6-hydroxydopamine</td>
<td align="left" colspan="1" rowspan="1">Reduced neuron loss</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Prion diseases</td>
<td align="left" colspan="1" rowspan="1">Lee JH <italic>et al</italic>., 2014</td>
<td align="left" colspan="1" rowspan="1">Human neuroblastoma cells exposed to PrP</td>
<td align="left" colspan="1" rowspan="1">Reduced cell death</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">HD</td>
<td align="left" colspan="1" rowspan="1">Luis-García <italic>et al</italic>., 2017</td>
<td align="left" colspan="1" rowspan="1">Rat quinolinic-acid-induced HD</td>
<td align="left" colspan="1" rowspan="1">Reduced mitochondrial dysfunction</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Jang <italic>et al</italic>., 2016</td>
<td align="left" colspan="1" rowspan="1">Mouse 3-NP-induced HD</td>
<td align="left" colspan="1" rowspan="1">Improved neurological behavior; reduced animal death; reduced neuron loss</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="11">Stroke and injury</td>
<td align="left" colspan="1" rowspan="1">Yu <italic>et al</italic>., 2017</td>
<td align="left" colspan="1" rowspan="1">Rat 60 min occlusive injury</td>
<td align="left" colspan="1" rowspan="1">Improved neurological function scores; reduced infarct volume</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Wu <italic>et al</italic>., 2012</td>
<td align="left" colspan="1" rowspan="1">Cultured rat cortical neurons 1 h glucose-oxygen deprivation</td>
<td align="left" colspan="1" rowspan="1">Reduced cell death and injury</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Soane <italic>et al</italic>., 2010</td>
<td align="left" colspan="1" rowspan="1">Cultured primary mouse immature hippocampal neurons exposed to oxygen-glucose deprivation</td>
<td align="left" colspan="1" rowspan="1">Reduced delayed neuronal death</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Soane <italic>et al</italic>., 2010</td>
<td align="left" colspan="1" rowspan="1">Cultured primary mouse immature hippocampal neurons exposed to hemin</td>
<td align="left" colspan="1" rowspan="1">Reduced neuron loss</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Black <italic>et al</italic>., 2015</td>
<td align="left" colspan="1" rowspan="1">Rat surgically-induced IUGR</td>
<td align="left" colspan="1" rowspan="1">Improved neurocognitive function in offspring; protection against loss of white matter and hippocampal neurons in offspring</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yin <italic>et al</italic>., 2015</td>
<td align="left" colspan="1" rowspan="1">Rat induced basal ganglia hemorrhage</td>
<td align="left" colspan="1" rowspan="1">Improved neurological function</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zhao <italic>et al</italic>., 2009</td>
<td align="left" colspan="1" rowspan="1">Mouse and rat induced ICH</td>
<td align="left" colspan="1" rowspan="1">Reduced neuron damage</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mao <italic>et al</italic>., 2011</td>
<td align="left" colspan="1" rowspan="1">Mouse compressive SCI</td>
<td align="left" colspan="1" rowspan="1">Improved locomotor function; reduced neuron loss</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Wang <italic>et al</italic>., 2012</td>
<td align="left" colspan="1" rowspan="1">Rat mechanical SCI</td>
<td align="left" colspan="1" rowspan="1">Reduced contusion volume; improved motor coordination</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Benedict <italic>et al</italic>., 2012</td>
<td align="left" colspan="1" rowspan="1">Rat contusive SCI</td>
<td align="left" colspan="1" rowspan="1">Improved locomotor function; increased 5-HT axons</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hong <italic>et al</italic>., 2010</td>
<td align="left" colspan="1" rowspan="1">Mouse and rat TBI</td>
<td align="left" colspan="1" rowspan="1">Improved neurological function; reduced contusion size; reduced neuron loss</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">Epilepsy</td>
<td align="left" colspan="1" rowspan="1">Pauletti <italic>et al</italic>., 2017</td>
<td align="left" colspan="1" rowspan="1">Rat electrically-induced epilepsy, co-treatment with N-acetylcysteine</td>
<td align="left" colspan="1" rowspan="1">Reduced frequency of seizures; reduced hippocampal neuron loss; improved cognitive function</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Socała <italic>et al</italic>., 2017</td>
<td align="left" colspan="1" rowspan="1">Mouse electrically-induced seizure</td>
<td align="left" colspan="1" rowspan="1">Potentiation of anti-convulsant effect of carbamazepine; at high concentrations, caused reduced seizure threshold</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Carrasco-Pozo <italic>et al</italic>., 2015</td>
<td align="left" colspan="1" rowspan="1">Mouse epilepsy and SE models</td>
<td align="left" colspan="1" rowspan="1">Increased ATP production; anticonvulsant effect</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6">Diabetes and neuropathy</td>
<td align="left" colspan="1" rowspan="1">Negi <italic>et al</italic>., 2011</td>
<td align="left" colspan="1" rowspan="1">Cultured peripheral neurons</td>
<td align="left" colspan="1" rowspan="1">Improved conduction velocity and blood flow</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Negi <italic>et al</italic>., 2011</td>
<td align="left" colspan="1" rowspan="1">Rat streptozocin-induced DM</td>
<td align="left" colspan="1" rowspan="1">Improved pain behavior</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yang <italic>et al</italic>., 2018</td>
<td align="left" colspan="1" rowspan="1">Mouse oxaliplatin-induced neuropathy</td>
<td align="left" colspan="1" rowspan="1">Improved pain sensation; improved mitochondrial function in DRG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Di <italic>et al</italic>., 2016</td>
<td align="left" colspan="1" rowspan="1">Rat nitroglycerin-induced hyperalgesia</td>
<td align="left" colspan="1" rowspan="1">Reduced tactile threshold</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Wang <italic>et al</italic>., 2016</td>
<td align="left" colspan="1" rowspan="1">Rat streptozocin-induced DM</td>
<td align="left" colspan="1" rowspan="1">Reduced apoptosis of hippocampal neurons; reduced memory impairment</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ren <italic>et al</italic>., 2018</td>
<td align="left" colspan="1" rowspan="1">Mouse streptozocin-and high fat diet-induced DM-associated retinopathy</td>
<td align="left" colspan="1" rowspan="1">Improved ONL thickness; reduced retinal cell apoptosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">Psychosis</td>
<td align="left" colspan="1" rowspan="1">Shirai <italic>et al</italic>., 2015</td>
<td align="left" colspan="1" rowspan="1">Mouse PCP-induced model of schizophrenia</td>
<td align="left" colspan="1" rowspan="1">Improved cognitive function</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mas <italic>et al</italic>., 2012</td>
<td align="left" colspan="1" rowspan="1">Human dopaminergic neuroblastoma cells exposed to antipsychotic medications and dopamine</td>
<td align="left" colspan="1" rowspan="1">Reduced cell death</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Shiina <italic>et al</italic>., 2015</td>
<td align="left" colspan="1" rowspan="1">Human patients with schizophrenia</td>
<td align="left" colspan="1" rowspan="1">Improved accuracy component of one card learning task</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GBM</td>
<td align="left" colspan="1" rowspan="1">Kumar <italic>et al</italic>., 2017</td>
<td align="left" colspan="1" rowspan="1">Cultured human monocytes in glioma-conditioned media</td>
<td align="left" colspan="1" rowspan="1">Increased mature dendritic cell development; reduced harmful monocyte transformation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Friedrich’s ataxia</td>
<td align="left" colspan="1" rowspan="1">Petrillo <italic>et al</italic>., 2017</td>
<td align="left" colspan="1" rowspan="1">Cultured frataxin-deficient motor neurons</td>
<td align="left" colspan="1" rowspan="1">Increased neurite number and amount of extension</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Hepatic encephalopathy</td>
<td align="left" colspan="1" rowspan="1">Hernandez-Rabaza <italic>et al</italic>., 2016</td>
<td align="left" colspan="1" rowspan="1">Rat ammonia-induced encephalopathy</td>
<td align="left" colspan="1" rowspan="1">Improved learning; improved motor coordination</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hernandez-Rabaza <italic>et al</italic>., 2016</td>
<td align="left" colspan="1" rowspan="1">Rat ammonia-induced encephalopathy</td>
<td align="left" colspan="1" rowspan="1">Improved spatial learning</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Herpes encephalitis</td>
<td align="left" colspan="1" rowspan="1">Schachtele <italic>et al</italic>., 2012</td>
<td align="left" colspan="1" rowspan="1">Mouse HSV encephalitis</td>
<td align="left" colspan="1" rowspan="1">Reduced neuronal damage; reduced neuroinflammation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">ASD</td>
<td align="left" colspan="1" rowspan="1">Singh <italic>et al</italic>., 2014</td>
<td align="left" colspan="1" rowspan="1">Human men with ASD</td>
<td align="left" colspan="1" rowspan="1">Improved measures of aberrant behavior, social responsiveness, social interaction, and verbal communication</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bent <italic>et al</italic>., 2018</td>
<td align="left" colspan="1" rowspan="1">Human children with ASD</td>
<td align="left" colspan="1" rowspan="1">Improved measures of social responsiveness</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="9">Toxins</td>
<td align="left" colspan="1" rowspan="1">Bi <italic>et al</italic>., 2017</td>
<td align="left" colspan="1" rowspan="1">Rat carbon monoxide exposure</td>
<td align="left" colspan="1" rowspan="1">Improved mitochondrial function; reduced hippocampal neuron damage</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Innamorato <italic>et al</italic>., 2008</td>
<td align="left" colspan="1" rowspan="1">Mouse LPS exposure</td>
<td align="left" colspan="1" rowspan="1">Reduced inflammatory markers in brain</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Townsend <italic>et al</italic>., 2017</td>
<td align="left" colspan="1" rowspan="1">Mouse LPS exposure</td>
<td align="left" colspan="1" rowspan="1">Reduced inflammatory markers in hippocampus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Dwivedi <italic>et al</italic>., 2016</td>
<td align="left" colspan="1" rowspan="1">Rat okadaic acid exposure</td>
<td align="left" colspan="1" rowspan="1">Improved memory; reduced neuron apoptosis in cortex and hippocampus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Wang <italic>et al</italic>., 2013</td>
<td align="left" colspan="1" rowspan="1">Zebrafish larvae cadmium exposure</td>
<td align="left" colspan="1" rowspan="1">Reduced olfactory tissue damage</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ishihara <italic>et al</italic>., 2012</td>
<td align="left" colspan="1" rowspan="1">Cultured rat hippocampus exposed to TBT</td>
<td align="left" colspan="1" rowspan="1">Reduced cell death</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chang <italic>et al</italic>., 2010</td>
<td align="left" colspan="1" rowspan="1">Cultured rat spinal cord exposed to glutamate</td>
<td align="left" colspan="1" rowspan="1">Reduced glutamate-associated neuronal damage</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Shavali <italic>et al</italic>., 2008</td>
<td align="left" colspan="1" rowspan="1">Human neuroblastoma cells exposed to arsenic and dopamine</td>
<td align="left" colspan="1" rowspan="1">Reduced cell death</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pearson <italic>et al</italic>., 2016</td>
<td align="left" colspan="1" rowspan="1">Cultured mouse neurons exposed to various neurotoxins</td>
<td align="left" colspan="1" rowspan="1">Reduced biochemical damage</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Aβ: Amyloid β, AD: Alzheimer’s disease, ACh: Acetylcholine, ASD: Autism spectrum disorder, DM: Diabetes mellitus, GBM: Glioblastoma multiforme, HD: Huntington’s disease, HSV: Herpes simplex virus, ICH: Intracerebral hemorrhage, IUGR: Intrauterine growth restriction, LPS: Lipopolysaccharide, MPTP: Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, ONL: Outer nuclear layer, PCP: Phencyclidine, PD: Parkinson’s disease, PrP: Prion protein, SCI: Spinal cord injury, SE: Status epilepticus, TBI: Traumatic brain injury, TBT: Tributyltin, 3-NP: 3-nitropropionic acid, DRG: Dorsal root ganglion, ATP: Adenosine triphosphate, 5-HT: 5-hydroxytryptamine (serotonin)</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec1-4">
<title>Neurodegenerative Diseases</title>
<p>SFN has many potential benefits in preventing and modifying the course and symptom burden of multiple neurodegenerative diseases. In the brains of transgenic mouse models of Alzheimer's disease, SFN reduces the amount of amyloid beta (Aβ) and phosphorylated tau proteins as well as their aggregation.[<xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref46">46</xref>] It also reduces memory deficits in mouse models.[<xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref46">46</xref>] The degradation of abnormal protein aggregates is likely promoted by the pro-autophagy pathways activated by SFN.[<xref ref-type="bibr" rid="ref19">19</xref>] The oxidative stress that the aggregated proteins cause in Alzheimer's disease is also reduced with SFN supplementation.[<xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref46">46</xref><xref ref-type="bibr" rid="ref47">47</xref>] SFN in a toxin-induced Alzheimer's mouse model led to sparing of cholinergic neuron loss in the hippocampus and medial septal region of the brain.[<xref ref-type="bibr" rid="ref48">48</xref>] SFN also protects cultured neural cells from the toxicity of methylglyoxal, a precursor of advanced glycation end products (AGEs) which is associated with Alzheimer's disease.[<xref ref-type="bibr" rid="ref12">12</xref>] Neural cell death due to Aβ exposure is also reduced with SFN supplementation by the activation of proteasomes.[<xref ref-type="bibr" rid="ref49">49</xref>] Similarly, SFN may also prevent or slow the process of normal brain aging and memory problems.[<xref ref-type="bibr" rid="ref50">50</xref>] Memory is protected by SFN when animals are exposed to various toxins, including streptozocin,[<xref ref-type="bibr" rid="ref31">31</xref>] MG132 (an inhibitor of proteasomes),[<xref ref-type="bibr" rid="ref50">50</xref>] and scopolamine.[<xref ref-type="bibr" rid="ref51">51</xref>]</p>
<p>Parkinson's disease also benefits from SFN administration. In mouse models of Parkinson's disease induced by various neurotoxins, including rotenone,[<xref ref-type="bibr" rid="ref23">23</xref>] 6-hydroxydopamine,[<xref ref-type="bibr" rid="ref32">32</xref><xref ref-type="bibr" rid="ref36">36</xref><xref ref-type="bibr" rid="ref52">52</xref>] 5-S-cysteinyl dopamine,[<xref ref-type="bibr" rid="ref53">53</xref>] and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,[<xref ref-type="bibr" rid="ref17">17</xref>] SFN administration protects neurons and reduces neuronal cell death of nigrostriatal dopaminergic neurons.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref32">32</xref><xref ref-type="bibr" rid="ref52">52</xref>] SFN also reduces motor deficits in toxin-induced animal models.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref32">32</xref>] Brain slice culture of rat nigrostriatal area also shows protection from toxin-induced Parkinson's damage.[<xref ref-type="bibr" rid="ref54">54</xref>] This protection is thought to be dependent on Nrf2 activation, with antioxidation and autophagy both participating in reducing damage.[<xref ref-type="bibr" rid="ref23">23</xref><xref ref-type="bibr" rid="ref32">32</xref><xref ref-type="bibr" rid="ref55">55</xref>] SFN may also protect cells from damage in prion diseases by activating autophagy to degrade the misfolded proteins.[<xref ref-type="bibr" rid="ref39">39</xref>] Furthermore, in animal models of Huntington's disease, SFN reduces striatal damage, decreases neuron death, and improves mitochondrial function.[<xref ref-type="bibr" rid="ref27">27</xref><xref ref-type="bibr" rid="ref42">42</xref>] SFN has a protective role in many neurodegenerative diseases that do not have any known cures, which makes it a quintessential agent for nervous system health. Research in humans is lacking, however, so its ability to decrease the risk of neurodegenerative diseases is unknown.</p>
</sec>
<sec id="sec1-5">
<title>Stroke and Injury</title>
<p>Hypoxic-ischemic injury, hemorrhage, and traumatic spinal cord injury also cause great amounts of damage to the nervous system, including the primary event as well as the secondary damage due to the resulting inflammatory reaction and oxidative stress from reperfusion.[<xref ref-type="bibr" rid="ref30">30</xref>] In hypoxic-ischemic injury such as infarction, SFN pre- and co-treatment reduces infarct volume and improves the neurological function in animals with induced infarcts.[<xref ref-type="bibr" rid="ref30">30</xref>] Protection is also seen in cultured neurons exposed to ischemia.[<xref ref-type="bibr" rid="ref33">33</xref><xref ref-type="bibr" rid="ref56">56</xref>] The same appears to be true for immature, developing nervous systems in the hypoxic conditions resulting from chronic placental insufficiency as well as infarct, with SFN administration reducing the loss of white matter, improving neurological function,[<xref ref-type="bibr" rid="ref57">57</xref>] and decreasing delayed neuronal cell death.[<xref ref-type="bibr" rid="ref56">56</xref>] Reduction in multiple inflammatory markers and immune cell activation is also seen with SFN use in ischemic injury.[<xref ref-type="bibr" rid="ref30">30</xref><xref ref-type="bibr" rid="ref57">57</xref><xref ref-type="bibr" rid="ref58">58</xref>] In the setting of intracerebral hemorrhage, SFN also improves neurological function[<xref ref-type="bibr" rid="ref20">20</xref>] and decreases the amount of damage due to free hemoglobin by inducing haptoglobin production in the brain.[<xref ref-type="bibr" rid="ref56">56</xref><xref ref-type="bibr" rid="ref59">59</xref>]</p>
<p>SFN is also protective in spinal cord injury in multiple animal models, including traumatic, contusive, and compressive cord injury models.[<xref ref-type="bibr" rid="ref38">38</xref><xref ref-type="bibr" rid="ref60">60</xref><xref ref-type="bibr" rid="ref61">61</xref>] Reductions in contusion volume, increased viable axons caudal to the lesion, and decreased neuronal cell death result from SFN administration.[<xref ref-type="bibr" rid="ref38">38</xref><xref ref-type="bibr" rid="ref60">60</xref><xref ref-type="bibr" rid="ref61">61</xref>] Improvements in motor function and coordination are also seen with SFN use in spinal cord-injured animals.[<xref ref-type="bibr" rid="ref38">38</xref><xref ref-type="bibr" rid="ref60">60</xref>] The same is true in traumatic brain injury in mice and rats, with SFN administration leading to decreased neuronal cell death, decreased contusion volume, and improvements in neurological function.[<xref ref-type="bibr" rid="ref18">18</xref>]</p>
</sec>
<sec id="sec1-6">
<title>Epilepsy</title>
<p>Epileptic seizures damage neurons by inducing oxidative stress in seizure locations.[<xref ref-type="bibr" rid="ref10">10</xref>] In animal models, SFN administration, when combined with the anti-oxidant N-acetylcysteine, reduces the frequency of seizures, improves cognitive function, and decreases hippocampal cell death.[<xref ref-type="bibr" rid="ref10">10</xref>] Low-dose SFN alone also potentiates the anti-seizure effects of carbamazepine, thus increasing the seizure threshold.[<xref ref-type="bibr" rid="ref62">62</xref>] SFN also raises the seizure threshold to protect against seizure occurrence.[<xref ref-type="bibr" rid="ref44">44</xref>] High-dose SFN, however, can decrease the seizure threshold.[<xref ref-type="bibr" rid="ref62">62</xref>] The administration of SFN in status epilepticus reduces lipid peroxidation in the hippocampus by protecting mitochondrial function and thus allowing the generation of more ATP in the energy-starved state induced by prolonged seizure.[<xref ref-type="bibr" rid="ref44">44</xref>]</p>
</sec>
<sec id="sec1-7">
<title>Diabetes and Neuropathy</title>
<p>AGEs are well-known neurotoxins that form due to high glucose concentrations as seen in diabetes mellitus (DM) and can cause peripheral neuropathy, cognitive dysfunction, and retinal damage.[<xref ref-type="bibr" rid="ref12">12</xref><xref ref-type="bibr" rid="ref28">28</xref><xref ref-type="bibr" rid="ref63">63</xref>] In cultured peripheral neurons, SFN improves multiple parameters of AGE-induced neuronal damage, including the normalization of conduction velocity and blood flow.[<xref ref-type="bibr" rid="ref28">28</xref>] In animal models of DM-induced neuropathy, pain behavior is lessened with SFN administration.[<xref ref-type="bibr" rid="ref28">28</xref>] Protection from neuropathy due to other causes, such as the chemotherapeutic drug oxaliplatin- and nitroglycerin-induced trigeminal nerve pain, is also conferred by SFN.[<xref ref-type="bibr" rid="ref22">22</xref><xref ref-type="bibr" rid="ref64">64</xref>] In the CNS, SFN prevents AGE formation[<xref ref-type="bibr" rid="ref65">65</xref>] and prevents memory dysfunction in DM animal models.[<xref ref-type="bibr" rid="ref31">31</xref>] Retinal degeneration due to AGEs is also reduced with SFN administration.[<xref ref-type="bibr" rid="ref63">63</xref>] Multiple mechanisms are at play in protection from AGE-induced damage, including the induction of thioredoxin,[<xref ref-type="bibr" rid="ref63">63</xref>] increased generation of GSH,[<xref ref-type="bibr" rid="ref12">12</xref>] decreased cleavage of caspase-3,[<xref ref-type="bibr" rid="ref31">31</xref>] and induction of the detoxifying glyoxalase-1[<xref ref-type="bibr" rid="ref12">12</xref>] which decreases AGE formation.[<xref ref-type="bibr" rid="ref65">65</xref>]</p>
</sec>
<sec id="sec1-8">
<title>Psychosis</title>
<p>The role of SFN in psychotic disorders is multifaceted and not yet fully elucidated. Both pre- and post-exposure administration of SFN in animals exposed to phencyclidine, a psychosis-inducing agent, reduces damage to the prefrontal cortex and improves cognitive dysfunction.[<xref ref-type="bibr" rid="ref66">66</xref>] The Nrf2 gene also has a genetic association with cognitive impairments in schizophrenic patients, thus implying that the Nrf2 pathway and SFN may play a key role in psychosis in humans.[<xref ref-type="bibr" rid="ref66">66</xref>] Furthermore, treatment with antipsychotic drugs including haloperidol, risperidone, and paliperidone causes neuronal damage due to the formation of oxidative stress.[<xref ref-type="bibr" rid="ref14">14</xref>] SFN reduces this oxidative stress in dopaminergic neurons and thus may prevent some of the untoward effects associated with the treatment of psychotic disorders.[<xref ref-type="bibr" rid="ref14">14</xref>] A small study of seven human patients with schizophrenia found that 8 weeks of SFN administration resulted in significant improvement in one of the three components of a test assessing working memory, but the study size may have limited its power to find other significant improvements.[<xref ref-type="bibr" rid="ref1">1</xref>]</p>
</sec>
<sec id="sec1-9">
<title>Other Diseases</title>
<p>As if the above protective effects are not enough, SFN also protects against neuronal damage in a variety of other diseases. Damage due to oxidative stress is reduced in models of Friedreich's ataxia, with SFN leading to an increased number of neurites, indicating increased plasticity.[<xref ref-type="bibr" rid="ref21">21</xref>] As briefly discussed previously, SFN may have a role in upsetting the immunosuppressed environment that protects glioblastoma multiforme.[<xref ref-type="bibr" rid="ref29">29</xref>] In hepatic encephalopathy in animals, SFN lowers the inflammatory response to hyperammonemia and normalizes cognitive function and coordination.[<xref ref-type="bibr" rid="ref25">25</xref><xref ref-type="bibr" rid="ref26">26</xref>] SFN administration also reduces neuronal damage induced by oxidative stress in mice with herpes encephalitis.[<xref ref-type="bibr" rid="ref7">7</xref>] Research regarding SFN use in autism spectrum disorder (ASD) is one area where some human studies have been done. A randomized controlled trial in human men with ASD revealed that 18 weeks of SFN administration improves multiple types of behavior, including reducing aberrant behaviors by 34%, increasing social responsiveness by 17%, as well as improving social interaction and verbal communication behaviors.[<xref ref-type="bibr" rid="ref67">67</xref>] A small study in children with ASD had similar results, with 12 weeks of SFN administration resulting in significantly improved social responsiveness, although this study found only a nonsignificant improvement in aberrant behavior.[<xref ref-type="bibr" rid="ref68">68</xref>] With such a wide array of disease protection, SFN may be utilized in many ways to help reduce nervous system disease burden.</p>
</sec>
<sec id="sec1-10">
<title>Toxins</title>
<p>Many neurotoxins exist with a variety of unique mechanisms of toxicity. The neuroprotection conferred by SFN appears to be quite broad, as evidenced by the reduction of neuronal damage in the setting of various toxin exposures. These include all the toxins used to induce models of disease mentioned above, as well as carbon monoxide,[<xref ref-type="bibr" rid="ref41">41</xref>] lipopolysaccharide found in Gram-negative bacteria,[<xref ref-type="bibr" rid="ref5">5</xref><xref ref-type="bibr" rid="ref37">37</xref>] the memory-impairing chemical okadaic acid,[<xref ref-type="bibr" rid="ref11">11</xref>] scopolamine,[<xref ref-type="bibr" rid="ref51">51</xref>] cadmium,[<xref ref-type="bibr" rid="ref69">69</xref>] the pesticide tributyltin,[<xref ref-type="bibr" rid="ref13">13</xref>] the excitotoxicity-inducing agent threohydroxyaspartate,[<xref ref-type="bibr" rid="ref70">70</xref>] arsenic,[<xref ref-type="bibr" rid="ref35">35</xref>] and multiple fungicides associated with genetic changes seen in autism, aging, and neurodegeneration.[<xref ref-type="bibr" rid="ref71">71</xref>] This broad scope of protection makes SFN a very useful tool to prevent or reduce neurotoxicity due to environmental or pharmaceutical toxin exposure.</p>
<sec id="sec2-1">
<title>Limitations and next steps</title>
<p>Several limitations are present in the currently available research. Nearly all SFN research regarding neuroprotection has been conducted with cultured neurons or animal models, apart from small trials regarding schizophrenia and ASD. While the results of this preclinical data are powerful, SFN use in humans with the diseases discussed will be crucial in understanding how well this animal research translates to human neurobiology. Without long-term prospective human cohort studies or controlled trials, it is difficult to assess whether the neuroprotection conferred by SFN will prevent the incidence of disease and burden of symptoms in preexisting disease. Another limitation is regarding the combination of SFN and antioxidants. Some researchers suggest that the concomitant use of SFN with antioxidants such as N-acetyl-l-cysteine reduces some the protective effects of SFN, specifically regarding the induction of autophagy.[<xref ref-type="bibr" rid="ref40">40</xref>] However, other research suggests that the combination can be more beneficial than either alone.[<xref ref-type="bibr" rid="ref10">10</xref>] This concept needs to be more fully elucidated to determine whether SFN with or without antioxidants will be most beneficial in each disease.</p>
<p>Further, only a few of the studies discussed mention possible neurotoxic effects of SFN, such as lowering the seizure threshold.[<xref ref-type="bibr" rid="ref62">62</xref>] Some researchers have concluded that SFN is a goitrogen because it can reduce uptake of iodine into the thyroid, but a human safety trial did not show reductions in thyroid function after SFN administration.[<xref ref-type="bibr" rid="ref4">4</xref>] Determining ideal dosages to maximize protection without causing detrimental effects will also be an important aspect of human trials.</p>
<p>Future research needs to address SFN use in humans with neurological diseases and disorders. This includes randomized controlled trials and longitudinal studies to assess the practical efficacy of SFN in neuroprotection. Research assessing the role of SFN as part of a multimodal treatment plan will also be important since SFN appears to have differential effects based on the concurrent treatments. Other research could look for even more efficacious Nrf2 activators or attempt to create them, like a melatonin-SFN hybrid molecule which may provide even further neuroprotection.[<xref ref-type="bibr" rid="ref72">72</xref>] There are currently multiple clinical trials ongoing regarding the effects of SFN supplementation in patients with schizophrenia and patients with ASD.[<xref ref-type="bibr" rid="ref73">73</xref>] Hopefully, more researchers find SFN to be a worthy compound to assess in other diseases as well.</p>
</sec>
</sec>
<sec id="sec1-11" sec-type="conclusion">
<title>Conclusion and Perspective</title>
<p>SFN is a powerful antioxidant and anti-inflammatory phytochemical with great promise in its ability to protect the nervous system from many diseases and toxins and reduce the symptomatic burden of multiple pervasive diseases [<xref ref-type="fig" rid="F1">Figure 1</xref>]. Research regarding long-term use in humans and disease outcomes will be important to determine its clinical utility. SFN, found naturally in high concentrations in broccoli sprouts, is a powerful example of how important food is to our health, and we must remember that while simple things like broccoli do not seem as powerful as human-made pharmaceuticals, they can truly be as or more important. The area of phytochemical use in prevention and damage reduction of neurological diseases is blossoming and may well be an important next step in reducing the risk of the many diseases we have assumed inevitable or incurable.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>A schematic view of the effects of sulforaphane in the nervous system. Sulforaphane provides neuroprotective effects by altering genetic expression of various damaging or protective mediators, which reduces cellular damage and harmful protein accumulation, finally resulting in multiple functional neurological improvements in many neurological disease states and toxin exposures</p>
</caption>
<graphic xlink:href="BC-5-74-g001"></graphic>
</fig>
<sec id="sec2-2">
<title>Financial support and sponsorship</title>
<p>This work was partially supported by Merit Review Award (I01RX-001964-01) from the US Department of Veterans Affairs Rehabilitation R and D Service.</p>
</sec>
<sec id="sec2-3" sec-type="COI-statement">
<title>Conflicts of interest</title>
<p>There are no conflicts of interest.</p>
</sec>
</sec>
</body>
<back>
<ref-list>
<ref id="ref1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kanahara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia</article-title>
<source/>Clin Psychopharmacol Neurosci
          <year>2015</year>
<volume>13</volume>
<fpage>62</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">25912539</pub-id>
</element-citation>
</ref>
<ref id="ref2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trio</surname>
<given-names>PZ</given-names>
</name>
<name>
<surname>Fujisaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tanigawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hisanaga</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sakao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>DX</given-names>
</name>
</person-group>
<article-title>DNA microarray highlights Nrf2-mediated neuron protection targeted by wasabi-derived isothiocyanates in IMR-32 cells</article-title>
<source/>Gene Regul Syst Bio
          <year>2016</year>
<volume>10</volume>
<fpage>73</fpage>
<lpage>83</lpage>
</element-citation>
</ref>
<ref id="ref3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways</article-title>
<source/>Mol Nutr Food Res
          <year>2017</year>
<volume>61</volume>
<fpage>1600194</fpage>
</element-citation>
</ref>
<ref id="ref4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Fahey</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Holtzclaw</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Stephenson</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Wade</surname>
<given-names>KL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: A clinical phase I study</article-title>
<source/>Nutr Cancer
          <year>2006</year>
<volume>55</volume>
<fpage>53</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">16965241</pub-id>
</element-citation>
</ref>
<ref id="ref5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Innamorato</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>García-Yagüe</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Ceballos</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The transcription factor Nrf2 is a therapeutic target against brain inflammation</article-title>
<source/>J Immunol
          <year>2008</year>
<volume>181</volume>
<fpage>680</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">18566435</pub-id>
</element-citation>
</ref>
<ref id="ref6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izumi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kataoka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Inose</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Akaike</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koyama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kume</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Neuroprotective effect of an Nrf2-ARE activator identified from a chemical library on dopaminergic neurons</article-title>
<source/>Eur J Pharmacol
          <year>2018</year>
<volume>818</volume>
<fpage>470</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">29154837</pub-id>
</element-citation>
</ref>
<ref id="ref7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schachtele</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lokensgard</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Modulation of experimental herpes encephalitis-associated neurotoxicity through sulforaphane treatment</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e36216</fpage>
<pub-id pub-id-type="pmid">22558388</pub-id>
</element-citation>
</ref>
<ref id="ref8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steele</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kersaitis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ooi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Münch</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells</article-title>
<source/>Redox Biol
          <year>2013</year>
<volume>1</volume>
<fpage>441</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">24191238</pub-id>
</element-citation>
</ref>
<ref id="ref9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>QQ</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>YR</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Sulforaphane inhibits the generation of amyloid-β oligomer and promotes spatial learning and memory in Alzheimer's disease (PS1V97L) transgenic mice</article-title>
<source/>J Alzheimers Dis
          <year>2018</year>
<volume>62</volume>
<fpage>1803</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">29614663</pub-id>
</element-citation>
</ref>
<ref id="ref10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pauletti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Terrone</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shekh-Ahmad</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Salamone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ravizza</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rizzi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy</article-title>
<source/>Brain
          <year>2017</year>
<volume>140</volume>
<fpage>1885</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">28575153</pub-id>
</element-citation>
</ref>
<ref id="ref11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dwivedi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rajasekar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hanif</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nath</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Sulforaphane ameliorates okadaic acid-induced memory impairment in rats by activating the Nrf2/HO-1 antioxidant pathway</article-title>
<source/>Mol Neurobiol
          <year>2016</year>
<volume>53</volume>
<fpage>5310</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">26433376</pub-id>
</element-citation>
</ref>
<ref id="ref12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angeloni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Malaguti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Barbalace</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Fabbri</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hrelia</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Neuroprotective effect of sulforaphane against methylglyoxal cytotoxicity</article-title>
<source/>Chem Res Toxicol
          <year>2015</year>
<volume>28</volume>
<fpage>1234</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">25933243</pub-id>
</element-citation>
</ref>
<ref id="ref13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishihara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kawami</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Tributyltin induces oxidative stress and neuronal injury by inhibiting glutathione S-transferase in rat organotypic hippocampal slice cultures</article-title>
<source/>Neurochem Int
          <year>2012</year>
<volume>60</volume>
<fpage>782</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">22449404</pub-id>
</element-citation>
</ref>
<ref id="ref14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gassó</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Trias</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lafuente</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress</article-title>
<source/>Fundam Clin Pharmacol
          <year>2012</year>
<volume>26</volume>
<fpage>712</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">21923690</pub-id>
</element-citation>
</ref>
<ref id="ref15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sedlak</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Nucifora</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Koga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shaffer</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Higgs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane augments glutathione and influences brain metabolites in human subjects: A clinical pilot study</article-title>
<source/>Mol Neuropsychiatry
          <year>2018</year>
<volume>3</volume>
<fpage>214</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">29888232</pub-id>
</element-citation>
</ref>
<ref id="ref16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizuno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kume</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Muto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Takada-Takatori</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Izumi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glutathione biosynthesis via activation of the nuclear factor E2-related factor 2 (Nrf2) – antioxidant-response element (ARE) pathway is essential for neuroprotective effects of sulforaphane and 6-(methylsulfinyl) hexyl isothiocyanate</article-title>
<source/>J Pharmacol Sci
          <year>2011</year>
<volume>115</volume>
<fpage>320</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">21358121</pub-id>
</element-citation>
</ref>
<ref id="ref17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jazwa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Innamorato</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Hesse</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fernández-Ruiz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental Parkinsonism</article-title>
<source/>Antioxid Redox Signal
          <year>2011</year>
<volume>14</volume>
<fpage>2347</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">21254817</pub-id>
</element-citation>
</ref>
<ref id="ref18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice</article-title>
<source/>Acta Pharmacol Sin
          <year>2010</year>
<volume>31</volume>
<fpage>1421</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">20953205</pub-id>
</element-citation>
</ref>
<ref id="ref19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pajares</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jiménez-Moreno</surname>
<given-names>N</given-names>
</name>
<name>
<surname>García-Yagüe</surname>
<given-names>ÁJ</given-names>
</name>
<name>
<surname>Escoll</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Ceballos</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Van Leuven</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes</article-title>
<source/>Autophagy
          <year>2016</year>
<volume>12</volume>
<fpage>1902</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">27427974</pub-id>
</element-citation>
</ref>
<ref id="ref20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>XP</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Mechanisms underlying the perifocal neuroprotective effect of the Nrf2-ARE signaling pathway after intracranial hemorrhage</article-title>
<source/>Drug Des Devel Ther
          <year>2015</year>
<volume>9</volume>
<fpage>5973</fpage>
<lpage>86</lpage>
</element-citation>
</ref>
<ref id="ref21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrillo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Piermarini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vasco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schirinzi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Carrozzo</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nrf2-inducers counteract neurodegeneration in Frataxin-silenced motor neurons: Disclosing new therapeutic targets for Friedreich's Ataxia</article-title>
<source/>Int J Mol Sci
          <year>2017</year>
<volume>18</volume>
<fpage>E2173</fpage>
<pub-id pub-id-type="pmid">29057804</pub-id>
</element-citation>
</ref>
<ref id="ref22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function</article-title>
<source/>Free Radic Biol Med
          <year>2018</year>
<volume>120</volume>
<fpage>13</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">29530794</pub-id>
</element-citation>
</ref>
<ref id="ref23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane protects against rotenone-induced neurotoxicity <italic>in vivo</italic>: Involvement of the mTOR, Nrf2, and autophagy pathways</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>32206</fpage>
<pub-id pub-id-type="pmid">27553905</pub-id>
</element-citation>
</ref>
<ref id="ref24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane attenuates microglia-mediated neuronal necroptosis through down-regulation of MAPK/NF-κB signaling pathways in LPS-activated BV-2 microglia</article-title>
<source/>Pharmacol Res
          <year>2018</year>
<volume>133</volume>
<fpage>218</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">29391237</pub-id>
</element-citation>
</ref>
<ref id="ref25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernandez-Rabaza</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cabrera-Pastor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Taoro-Gonzalez</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gonzalez-Usano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Agusti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Balzano</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia</article-title>
<source/>J Neuroinflammation
          <year>2016</year>
<volume>13</volume>
<fpage>83</fpage>
<pub-id pub-id-type="pmid">27090509</pub-id>
</element-citation>
</ref>
<ref id="ref26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernández-Rabaza</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cabrera-Pastor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Taoro-González</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Malaguarnera</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Agustí</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Llansola</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hyperammonemia induces glial activation, neuroinflammation and alters neurotransmitter receptors in hippocampus, impairing spatial learning: Reversal by sulforaphane</article-title>
<source/>J Neuroinflammation
          <year>2016</year>
<volume>13</volume>
<fpage>41</fpage>
<pub-id pub-id-type="pmid">26883214</pub-id>
</element-citation>
</ref>
<ref id="ref27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>IH</given-names>
</name>
</person-group>
<article-title>Sulforaphane ameliorates 3-nitropropionic acid-induced striatal toxicity by activating the keap1-Nrf2-ARE pathway and inhibiting the MAPKs and NF-κB pathways</article-title>
<source/>Mol Neurobiol
          <year>2016</year>
<volume>53</volume>
<fpage>2619</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">26096705</pub-id>
</element-citation>
</ref>
<ref id="ref28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Negi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Nrf2 and NF-κB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes</article-title>
<source/>Curr Neurovasc Res
          <year>2011</year>
<volume>8</volume>
<fpage>294</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="pmid">22023613</pub-id>
</element-citation>
</ref>
<ref id="ref29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>de Mooij</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Kaptzan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane</article-title>
<source/>PLoS One
          <year>2017</year>
<volume>12</volume>
<fpage>e0179012</fpage>
<pub-id pub-id-type="pmid">28666020</pub-id>
</element-citation>
</ref>
<ref id="ref30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>FZ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane improves outcomes and slows cerebral ischemic/reperfusion injury via inhibition of NLRP3 inflammasome activation in rats</article-title>
<source/>Int Immunopharmacol
          <year>2017</year>
<volume>45</volume>
<fpage>74</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">28189971</pub-id>
</element-citation>
</ref>
<ref id="ref31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane prevents neuronal apoptosis and memory impairment in diabetic rats</article-title>
<source/>Cell Physiol Biochem
          <year>2016</year>
<volume>39</volume>
<fpage>901</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">27497670</pub-id>
</element-citation>
</ref>
<ref id="ref32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morroni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tarozzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sita</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bolondi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zolezzi Moraga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Cantelli-Forti</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease</article-title>
<source/>Neurotoxicology
          <year>2013</year>
<volume>36</volume>
<fpage>63</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">23518299</pub-id>
</element-citation>
</ref>
<ref id="ref33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane protects primary cultures of cortical neurons against injury induced by oxygen-glucose deprivation/reoxygenation via antiapoptosis</article-title>
<source/>Neurosci Bull
          <year>2012</year>
<volume>28</volume>
<fpage>509</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">23054633</pub-id>
</element-citation>
</ref>
<ref id="ref34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maciel-Barón</surname>
<given-names>LÁ</given-names>
</name>
<name>
<surname>Morales-Rosales</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Silva-Palacios</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rodríguez-Barrera</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>García-Álvarez</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Luna-López</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The secretory phenotype of senescent astrocytes isolated from wistar newborn rats changes with anti-inflammatory drugs, but does not have a short-term effect on neuronal mitochondrial potential</article-title>
<source/>Biogerontology
          <year>2018</year>
<volume>19</volume>
<fpage>415</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">30097900</pub-id>
</element-citation>
</ref>
<ref id="ref35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shavali</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sens</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Synergistic neurotoxic effects of arsenic and dopamine in human dopaminergic neuroblastoma SH-SY5Y cells</article-title>
<source/>Toxicol Sci
          <year>2008</year>
<volume>102</volume>
<fpage>254</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">18079140</pub-id>
</element-citation>
</ref>
<ref id="ref36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morroni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sita</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Djemil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>D'Amico</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pruccoli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cantelli-Forti</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison of adaptive neuroprotective mechanisms of sulforaphane and its interconversion product erucin in <italic>in vitro</italic> and <italic>in vivo</italic> models of Parkinson's disease</article-title>
<source/>J Agric Food Chem
          <year>2018</year>
<volume>66</volume>
<fpage>856</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">29307179</pub-id>
</element-citation>
</ref>
<ref id="ref37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Townsend</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>Sulforaphane reduces lipopolysaccharide-induced proinflammatory markers in hippocampus and liver but does not improve sickness behavior</article-title>
<source/>Nutr Neurosci
          <year>2017</year>
<volume>20</volume>
<fpage>195</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="pmid">26639573</pub-id>
</element-citation>
</ref>
<ref id="ref38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Transcription factor Nrf2 protects the spinal cord from inflammation produced by spinal cord injury</article-title>
<source/>J Surg Res
          <year>2011</year>
<volume>170</volume>
<fpage>e105</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="pmid">21764072</pub-id>
</element-citation>
</ref>
<ref id="ref39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SY</given-names>
</name>
</person-group>
<article-title>Sulforaphane-induced autophagy flux prevents prion protein-mediated neurotoxicity through AMPK pathway</article-title>
<source/>Neuroscience
          <year>2014</year>
<volume>278</volume>
<fpage>31</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">25130556</pub-id>
</element-citation>
</ref>
<ref id="ref40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>YH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane induces autophagy through ERK activation in neuronal cells</article-title>
<source/>FEBS Lett
          <year>2014</year>
<volume>588</volume>
<fpage>3081</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">24952354</pub-id>
</element-citation>
</ref>
<ref id="ref41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulphoraphane improves neuronal mitochondrial function in brain tissue in acute carbon monoxide poisoning rats</article-title>
<source/>Basic Clin Pharmacol Toxicol
          <year>2017</year>
<volume>120</volume>
<fpage>541</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">27983767</pub-id>
</element-citation>
</ref>
<ref id="ref42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luis-García</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Limón-Pacheco</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Serrano-García</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hernández-Pérez</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Pedraza-Chaverri</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Orozco-Ibarra</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane prevents quinolinic acid-induced mitochondrial dysfunction in rat striatum</article-title>
<source/>J Biochem Mol Toxicol
          <year>2017</year>
<volume>31</volume>
<fpage>e21837</fpage>
</element-citation>
</ref>
<ref id="ref43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denzer</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Münch</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Friedland</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds</article-title>
<source/>Pharmacol Res
          <year>2016</year>
<volume>103</volume>
<fpage>80</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">26626189</pub-id>
</element-citation>
</ref>
<ref id="ref44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carrasco-Pozo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Borges</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Sulforaphane is anticonvulsant and improves mitochondrial function</article-title>
<source/>J Neurochem
          <year>2015</year>
<volume>135</volume>
<fpage>932</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">26365487</pub-id>
</element-citation>
</ref>
<ref id="ref45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Effects of sulforaphane on neural stem cell proliferation and differentiation</article-title>
<source/>Genesis
          <year>2017</year>
<volume>55</volume>
<fpage>e23022</fpage>
</element-citation>
</ref>
<ref id="ref46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>JS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane upregulates the heat shock protein co-chaperone CHIP and clears amyloid-β and tau in a mouse model of Alzheimer's disease</article-title>
<source/>Mol Nutr Food Res
          <year>2018</year>
<volume>62</volume>
<fpage>e1800240</fpage>
<pub-id pub-id-type="pmid">29714053</pub-id>
</element-citation>
</ref>
<ref id="ref47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Ehrlich</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model</article-title>
<source/>Amyloid
          <year>2013</year>
<volume>20</volume>
<fpage>7</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">23253046</pub-id>
</element-citation>
</ref>
<ref id="ref48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer's disease-like lesions</article-title>
<source/>Int J Mol Sci
          <year>2014</year>
<volume>15</volume>
<fpage>14396</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="pmid">25196440</pub-id>
</element-citation>
</ref>
<ref id="ref49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kwak</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Protection against amyloid beta cytotoxicity by sulforaphane: Role of the proteasome</article-title>
<source/>Arch Pharm Res
          <year>2009</year>
<volume>32</volume>
<fpage>109</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="pmid">19183883</pub-id>
</element-citation>
</ref>
<ref id="ref50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sunkaria</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bhardwaj</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Halder</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sandhir</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Sulforaphane attenuates postnatal proteasome inhibition and improves spatial learning in adult mice</article-title>
<source/>J Nutr Biochem
          <year>2018</year>
<volume>51</volume>
<fpage>69</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="pmid">29096318</pub-id>
</element-citation>
</ref>
<ref id="ref51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane alleviates scopolamine-induced memory impairment in mice</article-title>
<source/>Pharmacol Res
          <year>2014</year>
<volume>85</volume>
<fpage>23</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">24836869</pub-id>
</element-citation>
</ref>
<ref id="ref52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>SZ</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Sulforaphane protects against 6-hydroxydopamine-induced cytotoxicity by increasing expression of heme oxygenase-1 in a PI3K/Akt-dependent manner</article-title>
<source/>Mol Med Rep
          <year>2012</year>
<volume>5</volume>
<fpage>847</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">22200816</pub-id>
</element-citation>
</ref>
<ref id="ref53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vauzour</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Buonfiglio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Corona</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chirafisi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vafeiadou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Angeloni</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane protects cortical neurons against 5-S-cysteinyl-dopamine-induced toxicity through the activation of ERK1/2, Nrf-2 and the upregulation of detoxification enzymes</article-title>
<source/>Mol Nutr Food Res
          <year>2010</year>
<volume>54</volume>
<fpage>532</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">20166144</pub-id>
</element-citation>
</ref>
<ref id="ref54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siebert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Desai</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Chandrasekaran</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fiskum</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jafri</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures</article-title>
<source/>J Neurosci Res
          <year>2009</year>
<volume>87</volume>
<fpage>1659</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">19125416</pub-id>
</element-citation>
</ref>
<ref id="ref55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protective effect of sulforaphane against dopaminergic cell death</article-title>
<source/>J Pharmacol Exp Ther
          <year>2007</year>
<volume>321</volume>
<fpage>249</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">17259450</pub-id>
</element-citation>
</ref>
<ref id="ref56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soane</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li Dai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Fiskum</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bambrick</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>Sulforaphane protects immature hippocampal neurons against death caused by exposure to hemin or to oxygen and glucose deprivation</article-title>
<source/>J Neurosci Res
          <year>2010</year>
<volume>88</volume>
<fpage>1355</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">19998483</pub-id>
</element-citation>
</ref>
<ref id="ref57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Black</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Juurlink</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Yager</surname>
<given-names>JY</given-names>
</name>
</person-group>
<article-title>Broccoli sprout supplementation during pregnancy prevents brain injury in the newborn rat following placental insufficiency</article-title>
<source/>Behav Brain Res
          <year>2015</year>
<volume>291</volume>
<fpage>289</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">26014855</pub-id>
</element-citation>
</ref>
<ref id="ref58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ping</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme</article-title>
<source/>Brain Res
          <year>2010</year>
<volume>1343</volume>
<fpage>178</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">20417626</pub-id>
</element-citation>
</ref>
<ref id="ref59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grotta</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroprotective role of haptoglobin after intracerebral hemorrhage</article-title>
<source/>J Neurosci
          <year>2009</year>
<volume>29</volume>
<fpage>15819</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">20016097</pub-id>
</element-citation>
</ref>
<ref id="ref60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>de Rivero Vaccari</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>German</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Marcillo</surname>
<given-names>AE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective after spinal cord injury</article-title>
<source/>J Neurotrauma
          <year>2012</year>
<volume>29</volume>
<fpage>936</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">21806470</pub-id>
</element-citation>
</ref>
<ref id="ref61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benedict</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Mountney</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hurtado</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Schnaar</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>AT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroprotective effects of sulforaphane after contusive spinal cord injury</article-title>
<source/>J Neurotrauma
          <year>2012</year>
<volume>29</volume>
<fpage>2576</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">22853439</pub-id>
</element-citation>
</ref>
<ref id="ref62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Socała</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nieoczym</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kowalczuk-Vasilev</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wyska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wlaź</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Increased seizure susceptibility and other toxicity symptoms following acute sulforaphane treatment in mice</article-title>
<source/>Toxicol Appl Pharmacol
          <year>2017</year>
<volume>326</volume>
<fpage>43</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">28412310</pub-id>
</element-citation>
</ref>
<ref id="ref63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Up-regulation thioredoxin inhibits advanced glycation end products-induced neurodegeneration</article-title>
<source/>Cell Physiol Biochem
          <year>2018</year>
<volume>50</volume>
<fpage>1673</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">30384364</pub-id>
</element-citation>
</ref>
<ref id="ref64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of the nuclear factor E2-related factor 2/anitioxidant response element alleviates the nitroglycerin-induced hyperalgesia in rats</article-title>
<source/>J Headache Pain
          <year>2016</year>
<volume>17</volume>
<fpage>99</fpage>
<pub-id pub-id-type="pmid">27778243</pub-id>
</element-citation>
</ref>
<ref id="ref65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mangiferin upregulates glyoxalase 1 through activation of Nrf2/ARE signaling in central neurons cultured with high glucose</article-title>
<source/>Mol Neurobiol
          <year>2017</year>
<volume>54</volume>
<fpage>4060</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">27318675</pub-id>
</element-citation>
</ref>
<ref id="ref66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shirai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ohi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamamori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0127244</fpage>
<pub-id pub-id-type="pmid">26107664</pub-id>
</element-citation>
</ref>
<ref id="ref67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Fahey</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Talalay</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane treatment of autism spectrum disorder (ASD)</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2014</year>
<volume>111</volume>
<fpage>15550</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">25313065</pub-id>
</element-citation>
</ref>
<ref id="ref68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bent</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lawton</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Widjaja</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fahey</surname>
<given-names>JW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli</article-title>
<source/>Mol Autism
          <year>2018</year>
<volume>9</volume>
<fpage>35</fpage>
<pub-id pub-id-type="pmid">29854372</pub-id>
</element-citation>
</ref>
<ref id="ref69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>EP</given-names>
</name>
</person-group>
<article-title>Role of Nrf2 antioxidant defense in mitigating cadmium-induced oxidative stress in the olfactory system of zebrafish</article-title>
<source/>Toxicol Appl Pharmacol
          <year>2013</year>
<volume>266</volume>
<fpage>177</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">23174481</pub-id>
</element-citation>
</ref>
<ref id="ref70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protective effect of combination of sulforaphane and riluzole on glutamate-mediated excitotoxicity</article-title>
<source/>Biol Pharm Bull
          <year>2010</year>
<volume>33</volume>
<fpage>1477</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">20823560</pub-id>
</element-citation>
</ref>
<ref id="ref71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearson</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>McCoy</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Salazar</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fragola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zylka</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of chemicals that mimic transcriptional changes associated with autism, brain aging and neurodegeneration</article-title>
<source/>Nat Commun
          <year>2016</year>
<volume>7</volume>
<fpage>11173</fpage>
<pub-id pub-id-type="pmid">27029645</pub-id>
</element-citation>
</ref>
<ref id="ref72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egea</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Buendia</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rada</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Melatonin-sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a ‘drug-prodrug’ mechanism of action</article-title>
<source/>Br J Pharmacol
          <year>2015</year>
<volume>172</volume>
<fpage>1807</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">25425158</pub-id>
</element-citation>
</ref>
<ref id="ref73">
<label>73</label>
<element-citation publication-type="webpage">
<article-title>U.S. National Library of Medicine. Search Results for “sulforaphane.”</article-title>
<source/>National Institute of Health. U.S. Department of Health and Human Services
          <date-in-citation>Last accessed on 2019 Feb 12</date-in-citation>
<comment>Available from: <uri xlink:href="http://Clinicaltrials.gov" xlink:type="simple">http://Clinicaltrials. gov</uri></comment>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>